Newsletter Subscription

Enter Name and Email

03 July 2013 - The Michael J Fox Foundation awards a second research grant to Neurolixis

Neurolixis Inc. has been awarded a second research grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to investigate the activity of novel serotonin 5-HT1A receptor agonists in models of Parkinson's disease.

The new one-year grant constitutes an expansion of a previous MJFF grant awarded to Neurolixis in December 2011, of which Adrian Newman-Tancredi, PhD, DSc, is Principal Investigator. This generated promising results which will be presented at MJFF's 7th Annual Parkinson's Disease Therapeutics Conference in New York City on October 24, 2013, and at the Society for Neuroscience meeting in San Diego, California, in November 2013. If the new studies are successful, Neurolixis aims to take a clinical candidate, NLX-112, into proof-of-concept Phase 2 clinical trials in Parkinson's disease patients.

Neurolixis is a biopharmaceutical venture in which Adrian serves as co-founder and Chief Scientific Officer.
The full press announcement can be found here.